



## **Invasive Prenatal (Fetal) Diagnostic Testing**

**Policy #** 00690

**Original Effective Date:** 11/13/2019

**Current Effective Date:** 12/11/2023

*Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.*

*Note: Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders is addressed separately in medical policy 00389.*

*Note: Chromosomal Microarray Testing for the Evaluation of Pregnancy Loss is addressed separately in medical policy 00449.*

*Note: Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies is addressed separately in medical policy 00536.*

*Note: Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions Using Cell-Free Fetal DNA is addressed separately in medical policy 00345.*

## **When Services Are Eligible for Coverage**

*Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:*

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

### **Chromosomal Microarray Testing**

Based on review of available data, in individuals who are undergoing invasive diagnostic prenatal (fetal) testing, the Company may consider chromosome microarray testing as an alternative to karyotyping to be **eligible for coverage\*\*** (see Policy Guidelines).

## **When Services May Be Eligible for Coverage**

*Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:*

- *Benefits are available in the member's contract/certificate, and*

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

- *Medical necessity criteria and guidelines are met.*

### **Single-Gene Disorders**

Based on review of available data, the Company may consider invasive diagnostic prenatal (fetal) testing for molecular analysis for single-gene disorders when a pregnancy has been identified as being at high-risk to be **eligible for coverage**.\*\*

### **Patient Selection Criteria**

Coverage eligibility will be considered for invasive diagnostic prenatal (fetal) testing for molecular analysis for single-gene disorders when **ANY** of the following high risk pregnancy criteria are met:

- For autosomal dominant conditions, at least one of the parents has a known pathogenic variant;

**OR**

- For autosomal recessive conditions:
  - Both parents are suspected to be carriers or are known to be carriers; **OR**
  - One parent is clinically affected and the other parent is suspected to be or is a known carrier;

**OR**

- For X-linked conditions: A parent is suspected to be or is a known carrier;

**AND, when ALL** of the following criteria are met:

- The natural history of the disease is well-understood, and there is a reasonable likelihood that the disease is one with high morbidity in the homozygous or compound heterozygous state; **AND**
- Any variants have high penetrance, **AND**
- The genetic test has adequate sensitivity and specificity to guide clinical decision making and residual risk is understood, **AND**
- An association of the marker with the disorder has been established.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

## When Services Are Considered Investigational

*Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.*

Based on review of available data, **IF** the above criteria for molecular analysis of single-gene disorders are not met, the company will consider invasive diagnostic prenatal (fetal) genetic testing to be **investigational**.\*

### Next-Generation Sequencing

Based on review of available data, the company considers the use of next-generation sequencing e.g. multigene panel testing, whole-exome sequencing, or whole-genome sequencing, in the setting of invasive prenatal testing to be **investigational**.\*

## Policy Guidelines

### **Fetal Malformations**

Fetal malformations identified by ultrasound, characterized as major or minor malformations, whether isolated or multiple, may be part of a genetic syndrome, despite a normal fetal karyotype.

Major malformations are structural defects that have a significant effect on function or social acceptability. They may be lethal or associated with possible survival with severe or moderate immediate or long-term morbidity. Examples by organ system include: genitourinary: renal agenesis (unilateral or bilateral), hypoplastic/cystic kidney; cardiovascular: complex heart malformations; musculoskeletal: osteochondrodysplasia/osteogenesis imperfecta, clubfoot, craniosynostosis; central nervous system: anencephaly, hydrocephalus, myelomeningocele; facial clefts; body wall: omphalocele/gastroschisis; and respiratory: cystic adenomatoid lung malformation.

### **Single-Gene Disorders**

An individual may be suspected of being a carrier if there is a family history of or ethnic predilection for a disease. Carrier screening is not recommended if the carrier rate is less than 1% in the general population.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

In most cases, before a prenatal diagnosis using molecular genetic testing can be offered, the familial variant must be identified, either in an affected relative or carrier parent(s). Therefore, panel testing in this setting would not be considered appropriate.

In some cases, the father may not be available for testing, and the risk assessment to the fetus will need to be estimated without knowing the father's genetic status.

### Genetics Nomenclature Update

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). The Society's nomenclature is recommended by the Human Variome Project, the Human Genome Organization, and the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology-"pathogenic," "likely pathogenic," "uncertain significance," "likely benign," and "benign"-to describe variants identified that cause Mendelian disorders.

**Table PG1. Nomenclature to Report on Variants Found in DNA**

Previous	Updated	Definition
Mutation	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

**Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification**

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

### Genetic Counseling

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

## **Background/Overview**

### **Prenatal Genetic Testing Methodologies**

The focus of this evidence review is the use of certain invasive prenatal genetic testing methodologies in the prenatal (fetal) setting to provide a framework for evaluating the clinical utility of diagnosing monogenic disorders in this setting. The purpose of prenatal genetic testing is to identify conditions that might affect the fetus, newborn, or mother to inform pregnancy management (eg, prenatal treatment, decisions about delivery location and personnel, or pregnancy termination).

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

Invasive fetal diagnostic testing can include obtaining fetal tissue for karyotyping, fluorescence in situ hybridization, chromosomal microarray (CMA) testing, quantitative polymerase chain reaction (PCR), next-generation sequencing, and multiplex ligation-dependent probe amplification.

This evidence review only addresses the following:

- the diagnosis of copy number variants (CNVs) using CMA technology
- the diagnosis of single-gene disorders, most of which are due to single nucleotide variants (SNVs) or very small deletions, and use molecular methods to diagnose (mainly PCR but also multiplex ligation-dependent probe amplification)
- Next-generation sequencing

This evidence review applies only if there is not a separate evidence review that outlines specific criteria for diagnostic testing. If a separate evidence review exists, then the criteria in it supersede the guidelines herein. This evidence review does NOT cover the use of:

- prenatal carrier testing
- preimplantation genetic diagnosis or screening
- noninvasive prenatal testing
- testing in the setting of fetal demise

Genetic disorders are generally categorized into 3 main groups: chromosomal, single gene, and multifactorial. Single-gene disorders (also known as monogenic) result from errors in a specific gene, whereas those that are chromosomal include larger aberrations that are numerical or structural. Invasive prenatal testing refers to the direct testing of fetal tissue, typically by chorionic villus sampling (CVS) or amniocentesis. Both procedures increase the risk of miscarriage. Chorionic villus sampling utilizes placental cells that are derived from the same fertilized egg as the fetus. The chorionic villi are collected for genetic evaluation under ultrasound guidance without entering the amniotic sac. During amniocentesis, a small sample of the fluid that surrounds the fetus is removed. This fluid contains cells that are shed primarily from the fetal skin, bladder, gastrointestinal tract, and amnion. Typically, CVS is done at earlier gestation than amniocentesis. Most times only one procedure is done; however, sometimes CVS has ambiguous results from maternal cell contamination or placental mosaicism such that amniocentesis might additionally be needed for clarification. Invasive prenatal procedures are usually performed in pregnancies of women who have been identified as having a fetus at increased risk for a chromosomal abnormality, or if there is a family history of a single-gene disorder. For confirming positive cell-free DNA results,

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

amniocentesis might be preferred over CVS to avoid potential false-positive results due to confined placental mosaicism.

### **Chromosomal Microarray Testing**

CMA technology has several advantages over karyotyping, including improved resolution (detection of smaller chromosomal variants that are undetectable using standard karyotyping) and, therefore, can result in higher rates of detection of pathogenic chromosomal abnormalities. However, there are disadvantages to CMA testing, including the detection of variants of uncertain significance (VUS) and the fact that it cannot detect certain types of chromosomal abnormalities, including balanced rearrangements.

CMA analyzes abnormalities at the chromosomal level and measures gains and losses of DNA (known as CNVs) throughout the genome. CMA testing detects CNVs by comparing a reference genomic sequence ("normal") with the corresponding patient sequence. Each sample has a different fluorescent label so that they can be distinguished, and both are cohybridized to a sample of a specific reference (also normal) DNA fragment of the known genomic locus. If the patient sequence is missing part of the normal sequence (deletion) or has the normal sequence plus additional genomic material within that genomic location (eg, a duplication of the same sequence), the sequence imbalance is detected as a difference in fluorescence intensity. For this reason, standard CMA (non-SNVs, see the following) cannot detect balanced CNVs (equal exchange of material between chromosomes) or sequence inversions (the same sequence is present in reverse base-pair order) because the fluorescence intensity would not change.

CMA analysis uses thousands of cloned or synthesized DNA fragments of known genomic loci immobilized on a glass slide (microarray) to conduct thousands of comparative reactions at the same time. The prepared sample and control DNA is hybridized to the fragments on the slide, and CNVs are determined by computer analysis of the array patterns and intensities of the hybridization signals. Array resolution is limited only by the average size of the fragment used and by the chromosomal distance between loci represented by the reference DNA fragments on the slide. High-resolution oligonucleotide arrays are capable of detecting changes at a resolution of up to 50 to 100 kilobases.

### ***Types of Chromosomal Microarray Technologies***

There are differences in CMA technology, most notably in the various types of microarrays. They can differ first by construction; the earliest versions used DNA fragments cloned from a bacterial

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

artificial chromosome. They have been largely replaced by oligonucleotide (oligos; short, synthesized DNA) arrays, which offer better reproducibility. Finally, arrays that detect hundreds of thousands of SNVs across the genome have some advantages as well. An SNV is a DNA variation in which a single nucleotide in the genomic sequence is altered. This variation can occur between 2 different individuals or between paired chromosomes from the same individual and may or may not cause disease. Oligo/SNV hybrid arrays have been constructed to merge the advantages of each.

The 2 types of microarrays both detect CNVs but they identify different types of genetic variation. The oligo arrays detect CNVs for relatively large deletions or duplications, including whole chromosome duplications (trisomies) but cannot detect triploidy. SNV arrays provide a genome-wide copy number analysis and can detect consanguinity, as well as triploidy and uniparental disomy.

Microarrays may be prepared by the laboratory using the technology, or more commonly by commercial manufacturers, and sold to laboratories that must qualify and validate the product for use in their assay, in conjunction with computerized software for interpretation. The proliferation of in-house developed and commercially available platforms prompted the American College of Medical Genetics and Genomics to publish guidelines for the design and performance expectations for clinical microarrays and associated software in the postnatal setting.

At this time, no guidelines have shown whether targeted or genome-wide arrays should be used or what regions of the genome should be covered. Both targeted and genome-wide arrays search the entire genome for CNVs, however, targeted arrays are designed to cover only clinically significant areas of the genome. The American College of Medical Genetics guidelines for designing microarrays has recommended probe enrichment in clinically significant areas of the genome to maximize the detection of known abnormalities. Depending on the laboratory that develops a targeted array, it can include as many or as few microdeletions and microduplication syndromes as thought to be needed. The advantage, and purpose, of targeted arrays, is to minimize the number of VUS.

Whole-genome CMA analysis has allowed for the characterization of several new genetic syndromes, with other potential candidates currently under study. However, whole-genome arrays also have the disadvantage of potentially high numbers of apparent false-positive results, because benign CNVs are also found in phenotypically normal populations; both benign and pathogenic

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

CNVs are continuously cataloged and, to some extent, made available in public reference databases to aid in clinical interpretation relevance.

### ***Clinical Relevance of Chromosomal Microarray Findings and Variants of Uncertain Significance***

CNVs are generally classified as pathogenic (known to be disease-causing), benign, or a VUS.

A CNV that is considered a VUS:

- has not been previously identified in a laboratory's patient population, or
- has not been reported in the medical literature, or
- is not found in publicly available databases, or
- does not involve any known disease-causing genes.

To determine clinical relevance (consistent association with a disease) of CNV findings, the following actions are taken:

- CNVs are confirmed by another method (eg, fluorescence in situ hybridization, multiplex ligation-dependent probe amplification, PCR).
- CNVs detected are checked against public databases and, if available, against private databases maintained by the laboratory. Known pathogenic CNVs associated with the same or similar phenotype as the patient are assumed to explain the etiology of the case; known benign CNVs are assumed to be nonpathogenic.
- A pathogenic etiology is additionally supported when a CNV includes a gene known to cause the phenotype when inactivated (microdeletion) or overexpressed (microduplication).
- The laboratory may establish a size cutoff; potentially pathogenic CNVs are likely to be larger than benign polymorphic CNVs; cutoffs for CNVs not previously reported typically range from 300 kilobases to 1 megabase.
- Parental studies are indicated when CNVs of appropriate size are detected and not found in available databases; CNVs inherited from a clinically normal parent are assumed to be benign variants whereas those appearing de novo are likely pathogenic; etiology may become more certain as other similar cases accrue.

The International Standards for Cytogenomic Arrays (ISCA) Consortium (2008) was organized; it established a public database containing de-identified whole-genome microarray data from a subset of the ISCA Consortium member clinical diagnostic laboratories. Array analysis was carried out on subjects with phenotypes including intellectual disability, autism, and developmental delay. As of

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

July 2018, nearly 10,500 "expert reviewed" variants are listed in the ClinVar database. Data are currently hosted on ClinGen.

Use of the database includes an intralaboratory curation process, whereby laboratories are alerted to any inconsistencies among their own reported CNVs or other variants, as well as any inconsistency with the ISCA "known" pathogenic and "known" benign lists. The intralaboratory conflict rate was initially about 3% overall; following the release of the first ISCA curated track, the intralaboratory conflict rate decreased to about 1.5%. A planned interlaboratory curation process, whereby a group of experts curates reported CNVs/variants across laboratories, is currently in progress.

The consortium proposed "an evidence-based approach to guide the development of content on chromosomal microarrays and to support the interpretation of clinically significant copy number variation." The proposal defines levels of evidence (from the literature and/or ISCA and other public databases) that describe how well or how poorly detected variants or CNVs correlate with phenotype. ISCA is also developing vendor-neutral recommendations for standards for the design, resolution, and content of cytogenomic arrays using an evidence-based process and an international panel of experts in clinical genetics, clinical laboratory genetics, genomics, and bioinformatics.

### ***Single-Gene (Mendelian) Disorders***

Single-gene (Mendelian) disorders include those with an inheritance mode of autosomal dominant or recessive, X-linked dominant or recessive. Women may be identified as being at increased risk for having a fetus with an inherited genetic condition because of previously affected pregnancies, a family history in a suggestive pattern of inheritance, or being a member of a subpopulation with elevated frequencies of certain autosomal recessive conditions.

Most Mendelian disorders are caused by SNVs or very small deletions or duplications. Monogenic variants are diagnosed by molecular methods, mainly PCR for SNVs but also other methods like multiplex ligation-dependent probe amplification for very small deletions and duplications. Approximately 5000 known disorders are inherited in this fashion. Diagnostic tests are currently available for most of the common monogenic disorders, as well as for a number of the more rare disorders. For most single-gene disorders, testing in the prenatal setting requires knowledge of the familial variants.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

### ***Next-Generation Sequencing***

Next-generation sequencing has been used to identify pathogenic variants in disease-associated genes in many Mendelian disorders. Approximately 85% of known disease-causing variants occur within 1% of the genome that encodes for proteins (exome). Therefore, whole-exome sequencing can cost-effectively capture the majority of protein-coding regions. However, concerns remain about technical complexity, coverage, bioinformatics, interpretation, VUSs, as well as ethical issues.

### ***Commercially Available Tests***

Many academic and commercial laboratories offer CMA testing and single-gene disorder testing. Many laboratories also offer reflex testing, which may be performed with microarray testing added if karyotyping is normal or unable to be performed (due to no growth of cells). The test should be cleared or approved by the U.S. Food and Drug Administration, or performed in a Clinical Laboratory Improvement Amendment-certified laboratory.

## **FDA or Other Governmental Regulatory Approval**

### **U.S. Food and Drug Administration (FDA)**

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

## **Rationale/Source**

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Invasive prenatal (fetal) diagnostic testing may be used to identify pathogenic genetic alterations in fetuses at increased risk based on prenatal screening or in women who choose to undergo diagnostic testing due to other risk factors. This evidence review only addresses the use of chromosomal

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

microarray (CMA) testing, molecular diagnosis of single-gene disorders, and next-generation sequencing.

### Summary of Evidence

For individuals who are undergoing invasive diagnostic prenatal (fetal) testing and who receive chromosomal microarray (CMA) testing, the evidence includes a systematic review and meta-analysis and prospective cohort and retrospective analyses comparing the diagnostic yield of CMA testing with that of karyotyping. Relevant outcomes are test accuracy, test validity, and changes in reproductive decision-making. CMA testing has a higher detection rate of pathogenic chromosomal alterations than karyotyping. CMA testing can yield results that have uncertain clinical significance; however, such results can be minimized by the use of targeted arrays, testing phenotypically normal parents for the copy number variant, and the continued accumulation of pathogenic variants in international databases. The highest yield of pathogenic copy number variants by CMA testing has been found in fetuses with malformations identified by ultrasound. Changes in reproductive decision-making could include decisions on the continuation of a pregnancy, enabling timely treatment of a condition that could be treated medically or surgically either in utero or immediately after birth, and birthing decisions. The American College of Obstetricians and Gynecologists has recommended CMA testing in women who are undergoing an invasive diagnostic procedure. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are undergoing invasive diagnostic prenatal (fetal) testing and who receive molecular testing for single-gene disorders, the evidence includes case series that may report disorders detected and test validity. Relevant outcomes are test accuracy, test validity, and changes in reproductive decision-making. For clinical validity, when there is a known pathogenic familial variant, the sensitivity and specificity of testing for the variant in other family members are expected to be very high. Changes in reproductive decision-making could include decisions on the continuation of the pregnancy, facilitating timely treatment of a condition medically or surgically either in utero or immediately after birth, decisions concerning the place of delivery (ie, tertiary care center), and route of delivery. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are undergoing invasive diagnostic prenatal (fetal) testing and who receive next-generation sequencing, the evidence is lacking. Relevant outcomes are test accuracy, test validity,

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

and changes in reproductive decision-making. There are concerns about the interpretation of data generated by next-generation sequencing and the data's clinical relevance. The clinical validity of next-generation sequencing in the prenatal setting is unknown. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### **Supplemental Information**

#### **Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

#### ***American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine***

In 2016, the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine offered recommendations on the use of chromosomal microarray (CMA) testing and next-generation sequencing in prenatal diagnosis (Committee Opinion Number 682):

- "Chromosomal microarray analysis is a method of measuring gains and losses of DNA throughout the human genome. It can identify chromosomal aneuploidy and other large changes in the structure of chromosomes that would otherwise be identified by standard karyotype analysis, as well as submicroscopic abnormalities that are too small to be detected by traditional modalities.
- Most genetic changes identified by chromosomal microarray analysis that typically are not identified on standard karyotype are not associated with increasing maternal age; therefore, the use of this test can be considered for all women, regardless of age, who undergo prenatal diagnostic testing.
- Prenatal chromosomal microarray analysis is recommended for a patient with a fetus with one or more major structural abnormalities identified on ultrasonographic examination and who is undergoing invasive prenatal diagnosis. This test typically can replace the need for fetal karyotype.
- In a patient with a structurally normal fetus who is undergoing invasive prenatal diagnostic testing, either fetal karyotyping or a chromosomal microarray analysis can be performed.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

- Comprehensive patient pretest and posttest genetic counseling from an obstetrician-gynecologist or other health care provider with genetics expertise regarding the benefits, limitations, and results of chromosomal microarray analysis is essential.
- Chromosomal microarray analysis should not be ordered without informed consent, which should include a discussion of the potential to identify findings of uncertain significance, nonpaternity, consanguinity, and adult-onset disease.
- The routine use of whole-genome or whole-exome sequencing for prenatal diagnosis is not recommended outside of the context of clinical trials until sufficient peer-reviewed data and validation studies are published."

This Committee Opinion was reaffirmed in 2023.

### ***International Society for Prenatal Diagnosis, et al.***

In 2018, the International Society for Prenatal Diagnosis, the Society for Maternal-Fetal Medicine, and the Perinatal Quality Foundation released a joint position statement on the use of prenatal exome and genome-wide sequencing for fetal diagnosis.<sup>26</sup> This initial position statement was replaced in 2022. The 2022 position statement provides suggestions for clinical use, as described in the clinical indications below:

1. "The current existing data support that prenatal sequencing is beneficial for the following indications:
  - a. A current pregnancy with a fetus having a major single anomaly or multiple organ system anomalies:
    - i. For which no genetic diagnosis was found after CMA and a clinical genetic expert review considers the phenotype suggestive of a possible genetic etiology.
    - ii. For which the multiple anomaly 'pattern' strongly suggests a single gene disorder with no prior genetic testing. As pES [prenatal exome sequencing] is not currently validated to detect all CNVs [copy number variants], CMA should be run before or in parallel with pES in this scenario.
  - b. A personal (maternal or paternal) history of a prior undiagnosed fetus (or child) affected with a major single or multiple anomalies:
    - i. With a recurrence of similar anomalies in the current pregnancy without a genetic diagnosis after karyotype or CMA for the current or prior

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

- undiagnosed pregnancy. Point a.i. above also applies in these circumstances.
- ii. When such parents present for preconception counseling and no sample is available from the affected proband, or if a fetal sample cannot be obtained in an ongoing pregnancy, it is considered appropriate to offer sequencing for both biological parents to look for shared carrier status for autosomal recessive mutations that might explain the fetal phenotype. However, where possible, obtaining tissue from a previous abnormal fetus or child for pES is preferable.
2. There is currently no evidence that supports routine testing (including upon parental request) on fetal tissue obtained from an invasive prenatal procedure (amniocentesis, CVS, cordocentesis, other) for indications other than fetal anomalies.
    - a. There may be special settings when prenatal sequencing in the absence of a fetal phenotype visible on prenatal imaging can be considered, such as with a strong family history of a recurrent childhood-onset severe genetic condition with no prenatal phenotype in previous children for whom no genetic evaluation was done and is not possible. Such scenarios should be reviewed by an expert multidisciplinary team preferentially in the context of a research protocol. If sequencing is done for this indication, it must be done as trio sequencing, using an appropriate analytical approach."

## U.S. Preventive Services Task Force Recommendations

Not applicable.

## Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

## Ongoing and Unpublished Clinical Trials

A search of [ClinicalTrials.gov](https://clinicaltrials.gov) in June 2023 did not identify any ongoing or unpublished trials that would likely influence this review.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

## **References**

1. Cherry AM, Akkari YM, Barr KM, et al. Diagnostic cytogenetic testing following positive noninvasive prenatal screening results: a clinical laboratory practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. Aug 2017; 19(8): 845-850. PMID 28726804
2. Grati FR, Malvestiti F, Ferreira JC, et al. Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results. *Genet Med*. Aug 2014; 16(8): 620-4. PMID 24525917
3. ClinGen: Clinical Genome Resource. ClinGen and ClinVar Partnership. 2018; <https://www.clinicalgenome.org/>.
4. Babkina N, Graham JM. New genetic testing in prenatal diagnosis. *Semin Fetal Neonatal Med*. Jun 2014; 19(3): 214-9. PMID 24315623
5. Sun Y, Zhang W, Wang Z, et al. Chromosomal microarray analysis vs. karyotyping for fetal ventriculomegaly: a meta-analysis. *Chin Med J (Engl)*. Sep 20 2021; 135(3): 268-275. PMID 34852409
6. Jansen FA, Blumenfeld YJ, Fisher A, et al. Array comparative genomic hybridization and fetal congenital heart defects: a systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. Jan 2015; 45(1): 27-35. PMID 25319878
7. Wapner RJ, Levy B. The impact of new genomic technologies in reproductive medicine. *Discov Med*. Jun 2014; 17(96): 313-8. PMID 24979251
8. Hillman SC, McMullan DJ, Hall G, et al. Use of prenatal chromosomal microarray: prospective cohort study and systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. Jun 2013; 41(6): 610-20. PMID 23512800
9. Robson SC, Chitty LS, Morris S, et al. Evaluation of Array Comparative genomic Hybridisation in prenatal diagnosis of fetal anomalies: a multicentre cohort study with cost analysis and assessment of patient, health professional and commissioner preferences for array comparative genomic hybridisation (Efficacy and Mechanism Evaluation No. 4.1). Southampton, UK: National Institute for Health Research; 2017.
10. Lovrecic L, Remec ZI, Volk M, et al. Clinical utility of array comparative genomic hybridisation in prenatal setting. *BMC Med Genet*. Nov 15 2016; 17(1): 81. PMID 27846804
11. Papoulidis I, Sotiriadis A, Siomou E, et al. Routine use of array comparative genomic hybridization (aCGH) as standard approach for prenatal diagnosis of chromosomal

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

- abnormalities. Clinical experience of 1763 prenatal cases. *Prenat Diagn.* Dec 2015; 35(13): 1269-77. PMID 26289927
12. Armengol L, Nevado J, Serra-Juhé C, et al. Clinical utility of chromosomal microarray analysis in invasive prenatal diagnosis. *Hum Genet.* Mar 2012; 131(3): 513-23. PMID 21975797
  13. Shaffer LG, Dabell MP, Fisher AJ, et al. Experience with microarray-based comparative genomic hybridization for prenatal diagnosis in over 5000 pregnancies. *Prenat Diagn.* Oct 2012; 32(10): 976-85. PMID 22865506
  14. Shaffer LG, Rosenfeld JA, Dabell MP, et al. Detection rates of clinically significant genomic alterations by microarray analysis for specific anomalies detected by ultrasound. *Prenat Diagn.* Oct 2012; 32(10): 986-95. PMID 22847778
  15. Wapner RJ, Martin CL, Levy B, et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. *N Engl J Med.* Dec 06 2012; 367(23): 2175-84. PMID 23215555
  16. Breman A, Pursley AN, Hixson P, et al. Prenatal chromosomal microarray analysis in a diagnostic laboratory; experience with 1000 cases and review of the literature. *Prenat Diagn.* Apr 2012; 32(4): 351-61. PMID 22467166
  17. Shi Y, Ma J, Xue Y, et al. The assessment of combined karyotype analysis and chromosomal microarray in pregnant women of advanced maternal age: a multicenter study. *Ann Transl Med.* Jul 2019; 7(14): 318. PMID 31475188
  18. Yi JL, Zhang W, Meng DH, et al. Epidemiology of fetal cerebral ventriculomegaly and evaluation of chromosomal microarray analysis versus karyotyping for prenatal diagnosis in a Chinese hospital. *J Int Med Res.* Nov 2019; 47(11): 5508-5517. PMID 31422728
  19. Xiang J, Ding Y, Song X, et al. Clinical Utility of SNP Array Analysis in Prenatal Diagnosis: A Cohort Study of 5000 Pregnancies. *Front Genet.* 2020; 11: 571219. PMID 33240322
  20. Stuurman KE, van der Mespel-Brouwer MH, Engels MAJ, et al. Isolated Increased Nuchal Translucency in First Trimester Ultrasound Scan: Diagnostic Yield of Prenatal Microarray and Outcome of Pregnancy. *Front Med (Lausanne).* 2021; 8: 737936. PMID 34733861
  21. Chen Y, Xie Y, Jiang Y, et al. The Genetic Etiology Diagnosis of Fetal Growth Restriction Using Single-Nucleotide Polymorphism-Based Chromosomal Microarray Analysis. *Front Pediatr.* 2021; 9: 743639. PMID 34722424
  22. Gill K, Sasaki J, Jayakar P, et al. Chromosomal microarray detects genetic risks of neurodevelopmental disorders in newborns with congenital heart disease. *Cardiol Young.* Aug 2021; 31(8): 1275-1282. PMID 33536103
  23. Kocheva SA, Plaseska-Karanfilska D, Trivodalieva S, et al. Prenatal diagnosis of spinal muscular atrophy in Macedonian families. *Genet Test.* Sep 2008; 12(3): 391-3. PMID 18752447

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

24. Chen WJ, Wu ZY, Lin MT, et al. Molecular analysis and prenatal prediction of spinal muscular atrophy in Chinese patients by the combination of restriction fragment length polymorphism analysis, denaturing high-performance liquid chromatography, and linkage analysis. Arch Neurol. Feb 2007; 64(2): 225-31. PMID 17296838
25. Vora NL, Romero ST, Ralston SJ, et al. Committee Opinion No.682: Microarrays and Next-Generation Sequencing Technology: The Use of Advanced Genetic Diagnostic Tools in Obstetrics and Gynecology. Obstet Gynecol. Dec 2016; 128(6): e262-e268. PMID 27875474
26. International Society for Prenatal Diagnosis. Joint Position Statement from the International Society for Prenatal Diagnosis (ISPD), the Society for Maternal Fetal Medicine (SMFM), and the Perinatal Quality Foundation (PQF) on the use of genome-wide sequencing for fetal diagnosis. Prenat Diagn. Jan 2018; 38(1): 6-9. PMID 29315690
27. Van den Veyver IB, Chandler N, Wilkins-Haug LE, et al. International Society for Prenatal Diagnosis Updated Position Statement on the use of genome-wide sequencing for prenatal diagnosis. Prenat Diagn. May 2022; 42(6): 796-803. PMID 35583085
28. ACOG Clinical. Microarrays and Next-Generation Sequencing Technology The Use of Advanced Genetic Diagnostic Tools in Obstetrics and Gynecology. Committee Opinion. Number 682. December 2016. Reaffirmed 2023.

## **Policy History**

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

11/07/2019	Medical Policy Committee review
11/13/2019	Medical Policy Implementation Committee approval. New policy.
11/05/2020	Medical Policy Committee review
11/11/2020	Medical Policy Implementation Committee approval. No change to coverage.
11/04/2021	Medical Policy Committee review
11/10/2021	Medical Policy Implementation Committee approval. No change to coverage.
02/15/2022	Coding update
11/03/2022	Medical Policy Committee review
11/09/2022	Medical Policy Implementation Committee approval. No change to coverage.
11/02/2023	Medical Policy Committee review
11/08/2023	Medical Policy Implementation Committee approval. No change to coverage.

Next Scheduled Review Date: 11/2024

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

### **Coding**

*The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)†, copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.*

*The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.*

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	81228, 81229, 81405
HCPCS	No codes
ICD-10 Diagnosis	All related Diagnoses

\*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
  1. Consultation with technology evaluation center(s);
  2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
  3. Reference to federal regulations.

**\*\*Medically Necessary (or "Medical Necessity")** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





## Invasive Prenatal (Fetal) Diagnostic Testing

Policy # 00690

Original Effective Date: 11/13/2019

Current Effective Date: 12/11/2023

**NOTICE:** If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

**NOTICE:** Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

**NOTICE:** Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.